ASC30 vs Efmedaglutide alfa
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
ASC30
Developed by Ascletis Pharma
NCT07002905 · Phase 2 · completed
The study randomly assigned 125 participants and used quadruple blinding with placebo control across seven cohorts. Its primary endpoint was percent change in body weight at Week 13, but the registry has not posted whether this endpoint was met.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: July 2028 · NCT07743463 (registry estimate)
Reported efficacy
Percent change in body weight from Baseline up to Week 13 (Baseline and Week 13): Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo (met)
Result source: NCT07002905
Efmedaglutide alfa · Shanmeining
Developed by TJ Biopharma Co., Ltd. and partners
NCT05997576 · Phase 3 · completed
The study was randomized, double-blind, and placebo-controlled, with 675 participants and clinical primary outcomes measuring weight loss.
Result from CSPC's HKEX voluntary announcement of 13 October 2025 on the NMPA acceptance of the efmedaglutide alfa (TG103) application. The announcement names no trial number; the link to NCT05997576 rests on design and timing (the only TG103 Phase 3 trial in non-diabetic overweight or obesity, 675 participants, primary completion 17 February 2025).
Reported efficacy
Proportion of participants with weight loss of ≥ 5% at week 40 (From baseline to week 40); Relative percentage change from baseline in body weight at week 40 (From baseline to week 40): Body weight vs placebo in overweight or obese adults (pivotal Phase 3): CSPC states the product significantly reduced body weight compared with placebo; no figures released. The announcement does not report the co-primary proportion with at least 5% weight loss (CSPC announcement, 13 October 2025).
Result source: NCT05997576
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ASC30 | Efmedaglutide alfa |
|---|---|---|
| Body weight, % change | —Trial running · NCT07743463 | —Not posted · NCT05997576 |
| Weight loss of 5% or more | —Trial running · NCT07743463 | —Not posted · NCT05997576 |
| Weight loss of 10% or more | —Trial running · NCT07743463 | —Not posted · NCT05997576 |
| Waist circumference, change (cm) | —Trial running · NCT07743463 | —Not posted · NCT05997576 |
Body weight, % change
- ASC30
- —Trial running · NCT07743463
- Efmedaglutide alfa
- —Not posted · NCT05997576
Weight loss of 5% or more
- ASC30
- —Trial running · NCT07743463
- Efmedaglutide alfa
- —Not posted · NCT05997576
Weight loss of 10% or more
- ASC30
- —Trial running · NCT07743463
- Efmedaglutide alfa
- —Not posted · NCT05997576
Waist circumference, change (cm)
- ASC30
- —Trial running · NCT07743463
- Efmedaglutide alfa
- —Not posted · NCT05997576
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ASC30
show 2 more results
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
ASC30
Developed by Ascletis Pharma
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2028 · NCT07743450 (registry estimate)
No aligned efficacy figure on record for this race.
Efmedaglutide alfa · Shanmeining
Developed by TJ Biopharma Co., Ltd. and partners
NCT06235086 · Phase 3 · completed
This was a randomized, quadruple-masked Phase 3 trial with 632 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-30. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Reported efficacy
Changes in glycosylated hemoglobin (HbA1c) from baseline at 28 weeks of treatment (Baseline through Week28): Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30). (met)
Result source: NCT06235086
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ASC30 | Efmedaglutide alfa |
|---|---|---|
| HbA1c, change | —Trial running · NCT07743450 | —Not posted · NCT06258148 |
| Body weight, change (kg) | —Trial running · NCT07743450 | —Not posted · NCT06258148 |
| HbA1c below 7% | —Trial running · NCT07743450 | —Not posted · NCT06258148 |
| Fasting plasma glucose, change | —Trial running · NCT07743450 | —Not posted · NCT06258148 |
| 3-point MACE (% with event) | —Trial running · NCT07743450 | —Not posted · NCT06258148 |
HbA1c, change
- ASC30
- —Trial running · NCT07743450
- Efmedaglutide alfa
- —Not posted · NCT06258148
Body weight, change (kg)
- ASC30
- —Trial running · NCT07743450
- Efmedaglutide alfa
- —Not posted · NCT06258148
HbA1c below 7%
- ASC30
- —Trial running · NCT07743450
- Efmedaglutide alfa
- —Not posted · NCT06258148
Fasting plasma glucose, change
- ASC30
- —Trial running · NCT07743450
- Efmedaglutide alfa
- —Not posted · NCT06258148
3-point MACE (% with event)
- ASC30
- —Trial running · NCT07743450
- Efmedaglutide alfa
- —Not posted · NCT06258148
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ASC30: no structured comparison results are available for Type 2 Diabetes.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · Efmedaglutide alfa's landscape